Since July 2023, the Therapeutic Goods Administration has permitted the use of psychedelic medicines in conjunction with psychotherapy for treatment-resistant depression and PTSD. This development underscores the importance of understanding clinician knowledge, attitudes, and readiness regarding psychedelic assisted therapy by clinicians who are eligible to refer for, or deliver, these therapies.
Little research has explored the relationship between knowledge of psychedelics, and interest or openness toward engaging with psychedelic assisted therapy. This informs the key aims of our research. We aim to understand whether knowledge predicts increased willingness to engage in psychedelic-assisted therapy and reduces stigma.
The findings may help shape policies and guidelines to ensure the safe and optimally beneficial administration of psychedelic-assisted therapies. Participants also have the chance to enter a draw for a $150 MasterCard.
The survey, which takes approximately 5-10 minutes to complete, can be found here: https://uqpsych.qualtrics.com/jfe/form/SV_aYteBT0Qe1bqROC
If you have any questions or require any further information, please do not hesitate to contact the lead investigator Lena Oestreich: email@example.com